Literature DB >> 19490818

ONTARGET: use of ramipril, telmisartan, or both in patients with high cardiovascular risks.

HoWon Lee1, Amgad N Makaryus, Samy I McFarlane.   

Abstract

Entities:  

Year:  2009        PMID： 19490818     DOI： 10.1007/s11892-009-0030-9

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  16 in total

Review 1.  Update on the role of the AT2 receptor.

Authors:  Robert M Carey
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-01       Impact factor: 2.894

2.  Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials.

Authors:  Samy I McFarlane; Jeffrey S Borer
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

3.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Authors:  M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

4.  Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.

Authors:  R M A van de Wal; H W M Plokker; D J A Lok; F Boomsma; F A L van der Horst; D J van Veldhuisen; W H van Gilst; A A Voors
Journal:  Int J Cardiol       Date:  2006-01-26       Impact factor: 4.164

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 6.  Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.

Authors:  Sarah E McDowell; Jamie J Coleman; R E Ferner
Journal:  BMJ       Date:  2006-05-05

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

Review 8.  Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.

Authors:  Samy I McFarlane; Ashok Kumar; James R Sowers
Journal:  Am J Cardiol       Date:  2003-06-19       Impact factor: 2.778

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.